Company: IOBT
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047744
Chunk: 8

Company: IO Biotech, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 8
---
 multiple pipeline candidates. Our product candidate, IO112, targets Arginase 1, which is over-expressed in solid tumors where MDSCs are known to play key roles in immune resistance. The Company plans to submit an IND for IO112 in 2025. We are also continuing to evaluate other targets within the TME, including TGFβ1, and intend to leverage our T-win platform to bring additional product candidates into the clinic over time which could be used alone or in combination with other candidates. We believe that targeting TGFβ1 expressing cells in the TME via a vaccine approach presents a novel and attractive way to modulate the pathway and drive therapeutic benefit in cancer setting. We plan to continue preclinical studies of a TGFβ1 vaccine in 2025;

•Strengthen our position in the immunotherapy field through the continuous innovation and expansion of our T-win platform. We have extensive knowledge about the characterization of immunosuppressive mechanisms in the TME and pharmacology. We plan to continue investing in our platform in order to stay at the forefront of developments in the immunotherapy space. Our platform is supported by a strong patent portfolio consisting of 17 different families, filed in all major markets. We plan to continue investing in intellectual property to support our platform and product candidates; 

•Maximize the value of our product candidates and pipeline by selectively entering into strategic collaborations. All of our compounds are home grown using the T-win platform, and we hold the worldwide development and commercial rights. In order to speed up the clinical development of our candidates, we are actively looking for strategic partnering opportunities. These partnerships are meant to provide additional resources and expertise to maximize the success of our development efforts, support the potential commercialization of our products globally and expand our life cycle management; and 

•Build a leading immune-modulatory, off-the-shelf therapeutic cancer vaccine company while maintaining a strong culture of innovation, valuing diversity and putting patients at the center of everything we do. We will continue to apply our deep understanding of the TME to the discovery and development of novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines that have the potential to provide breakthroughs for cancer patients. We place a high value on the diversity of our team – including gender and background – to foster this culture of innovation. 

Our Approach to Therapeutic Cancer Vaccines 

Our product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. We believe this represents a paradigm